You might know you need to conduct drug metabolism and pharmacokinetic (DMPK) analysis, but which tests are right for your project? And are you doing them at the right time? When building your preclinical strategy, these questions matter—and that’s true now more than ever, as new drug classes and targets emerge.
September 30, 2020
- Receptor Mediated Therapies in the Clinic: From Targeting to Impact
- A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
- Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking
- Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
- Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
Receptor Mediated Therapies in the Clinic: From Targeting to Impact
Your browser does not support the video tag. Receptor mediated therapies have fundamentally changed how cancer is treated in the clinic. What began ...
A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
In cancer drug development, monotherapies often lose ground when tumors adapt. This is especially true for KRASmutant non–small cell lung cancers ...
Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking
Despite decades of investment in oncology drug development, the translational pipeline from preclinical models to clinical success remains ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
